<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PAMIDRONATE DISODIUM- pamidronate disodium injection, solution </strong><br>APP Pharmaceuticals, LLC<br></p></div>
<h1>Pamidronate Disodium Injection</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="d304b6e6-be45-4d5c-856b-d93aa0014f19"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Pamidronate Disodium Injection is a bone-resorption inhibitor available as a sterile, aqueous solution in 30 mg or 90 mg vials for intravenous administration.  Each mL of the 30 mg vial contains: 3 mg pamidronate disodium; 47 mg mannitol, USP; Water for Injection, USP, q.s.; phosphoric acid to adjust pH.  Each mL of the 90 mg vial contains: 9 mg pamidronate disodium, 37.5 mg mannitol, USP; Water for Injection, USP, q.s.; phosphoric acid to adjust pH.  Pamidronate disodium, a member of the group of chemical compounds known as bisphosphonates, is an analog of pyrophosphate.  Pamidronate disodium is designated chemically as phosphonic acid (3-amino-1-hydroxypropylidene) bis-, disodium salt, and its structural formula is:</p>
<p><img alt="Pamidronate Disodium Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad1b83f9-ddf7-44b7-9234-77d6872e4825&amp;name=pamidronate-disodium-injection-figure-1-pamidronatestructure.jpg"></p>
<p><span class="Bold"><span class="Emphasis">C<span class="Sub">3</span>H<span class="Sub">9</span>NO<span class="Sub">7</span>P<span class="Sub">2</span>Na<span class="Sub">2</span>                                                          </span></span><span class="Bold"><span class="Emphasis">M.W. 279.03</span></span></p>
<p><span class="Italics"><span class="Emphasis">Inactive Ingredients</span></span>.  Mannitol, USP, and phosphoric acid (for adjustment of pH to 6.5).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="b54f5735-ce34-44b8-98ea-6371f3f4386f"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The principal pharmacologic action of pamidronate disodium is inhibition of bone resorption.  Although the mechanism of antiresorptive action is not completely understood, several factors are thought to contribute to this action.  Pamidronate disodium adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone.  <span class="Italics"><span class="Emphasis">In vitro</span></span> studies also suggest that inhibition of osteoclast activity contributes to inhibition of bone resorption.  In animal studies, at doses recommended for the treatment of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, pamidronate disodium inhibits bone resorption apparently without inhibiting bone formation and mineralization.  Of relevance to the treatment of <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> is the finding that pamidronate disodium inhibits the accelerated bone resorption that results from osteoclast <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> induced by various tumors in animal studies.</p>
<div class="Section" data-sectionCode="34090-1">
<a name="c358522b-c3d4-4bf3-83b8-60b2b3910ebf"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics<br>
</h2>
<p class="First">Cancer patients (n=24) who had minimal or no bony involvement were given an intravenous infusion of 30, 60, or 90 mg of pamidronate disodium over 4 hours and 90 mg of pamidronate disodium over 24 hours (Table 1).</p>
<p><span class="Bold Italics"><span class="Emphasis">Distribution</span></span></p>
<p>The mean ± SD body retention of pamidronate was calculated to be 54 ± 16% of the dose over 120 hours.</p>
<p><span class="Bold Italics"><span class="Emphasis">Metabolism</span></span></p>
<p>Pamidronate is not metabolized and is exclusively eliminated by renal excretion.</p>
<p><span class="Bold Italics"><span class="Emphasis">Excretion</span></span></p>
<p>After administration of 30, 60, and 90 mg of pamidronate disodium over 4 hours, and 90 mg of pamidronate disodium over 24 hours, an overall mean ± SD of 46 ± 16% of the drug was excreted unchanged in the urine within 120 hours.  Cumulative urinary excretion was linearly related to dose.  The mean ± SD elimination half-life is 28 ± 7 hours.  Mean ± SD total and renal clearances of pamidronate were 107 ± 50 mL/min and 49 ± 28 mL/min, respectively.  The rate of elimination from bone has not been determined.</p>
<p><span class="Bold Italics"><span class="Emphasis">Special Populations</span></span></p>
<p>There are no data available on the effects of age, gender, or race on the pharmacokinetics of pamidronate.</p>
<p><span class="Italics"><span class="Emphasis">Pediatric</span></span></p>
<p>Pamidronate is not labeled for use in the pediatric population.</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></span></p>
<p>The pharmacokinetics of pamidronate were studied in cancer patients (n=19) with normal and varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  Each patient received a single 90 mg dose of pamidronate disodium infused over 4 hours.  The renal clearance of pamidronate in patients was found to closely correlate with creatinine clearance (see Figure 1).  A trend toward a lower percentage of drug excreted unchanged in urine was observed in renally impaired patients.  Adverse experiences noted were not found to be related to changes in renal clearance of pamidronate.  Given the recommended dose, 90 mg infused over 4 hours, excessive accumulation of pamidronate in renally impaired patients is not anticipated if pamidronate disodium is administered on a monthly basis.</p>
<p> </p>
<span class="Bold"><span class="Emphasis">Figure 1: Pamidronate renal clearance as a function of creatinine clearance in patients with normal and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  The lines are the mean prediction line and 95% confidence intervals.
 
</span></span><p><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad1b83f9-ddf7-44b7-9234-77d6872e4825&amp;name=pamidronate-disodium-injection-figure-2-pamidronatefig1.jpg"></p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></span></p>
<p>The pharmacokinetics of pamidronate were studied in male cancer patients at risk for bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> with normal hepatic function (n=6) and mild to moderate hepatic dysfunction (n=7).  Each patient received a single 90 mg dose of pamidronate disodium infused over 4 hours.  Although there was a statistically significant difference in the pharmacokinetics between patients with normal and impaired hepatic function, the difference was not considered clinically relevant.  Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> exhibited higher mean AUC (53%) and C<span class="Sub">max</span> (29%), and decreased plasma clearance (33%) values.  Nevertheless, pamidronate was still rapidly cleared from the plasma.  Drug levels were not detectable in patients by 12 to 36 hours after drug infusion.  Because pamidronate disodium is administered on a monthly basis, drug accumulation is not expected.  No changes in pamidronate disodium dosing regimen are recommended for patients with mild to moderate abnormal hepatic function.  Pamidronate disodium has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ae538a0e-2c69-4059-9c21-1b9b381fbd39"></a><a name="section-2.2"></a><p></p>
<h2>Drug-Drug Interactions<br>
</h2>
<p class="First">There are no human pharmacokinetic data for drug interactions with pamidronate disodium.</p>
<p><span class="Bold"><span class="Emphasis">Table 1 </span></span></p>
<p><span class="Bold"><span class="Emphasis">Mean (SD, CV%) Pamidronate Pharmacokinetic Parameters in Cancer Patients</span></span><span class="Bold"><span class="Emphasis"> (n=6 for each group)</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">Dose</p>
<p>(Infusion</p>
<p>Rate)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">Maximum</p>
<p>Concentration</p>
<p>(mcg/mL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">Percent</p>
<p>of Dose</p>
<p>Excreted</p>
<p>in Urine</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">Total</p>
<p>Clearance</p>
<p>(mL/min)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">Renal</p>
<p>Clearance</p>
<p>(mL/min)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">30 mg</p>
<p>(4 hrs)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">0.73</p>
<p>(0.14, 19.1%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">43.9</p>
<p>(14, 31.9%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">136</p>
<p>(44, 32.4%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">58</p>
<p>(27, 46.5%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">60 mg</p>
<p>(4 hrs)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">1.44</p>
<p>(0.57, 39.6%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">47.4</p>
<p>(47.4, 54.4%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">88</p>
<p>(56, 63.6%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">42</p>
<p>(28, 66.7%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">90 mg</p>
<p>(4 hrs)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">2.61</p>
<p>(0.74, 28.3%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">45.3</p>
<p>(25.8, 56.9%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">103</p>
<p>(37, 35.9%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">44</p>
<p>(16, 36.4%)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">90 mg</p>
<p>(24 hrs)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">1.38</p>
<p>(1.97, 142.7%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">47.5</p>
<p>(10.2, 21.5%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">101</p>
<p>(58, 57.4%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">52</p>
<p>(42, 80.8%)</p>
</td>
</tr>
</tbody></table>
<p>After intravenous administration of radiolabeled pamidronate in rats, approximately 50% to 60% of the compound was rapidly adsorbed by bone and slowly eliminated from the body by the kidneys.  In rats given 10 mg/kg bolus injections of radiolabeled pamidronate disodium, approximately 30% of the compound was found in the liver shortly after administration and was then redistributed to bone or eliminated by the kidneys over 24 to 48 hours.  Studies in rats injected with radiolabeled pamidronate disodium showed that the compound was rapidly cleared from the circulation and taken up mainly by bones, liver, spleen, teeth, and tracheal cartilage.  Radioactivity was eliminated from most soft tissues within 1 to 4 days; was detectable in liver and spleen for 1 and 3 months, respectively; and remained high in bones, trachea, and teeth for 6 months after dosing.  Bone uptake occurred preferentially in areas of high bone turnover.  The terminal phase of elimination half-life in bone was estimated to be approximately 300 days.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="a117469a-b14b-4b4c-bab6-ade94d895ea8"></a><a name="section-2.3"></a><p></p>
<h2>Pharmacodynamics<br>
</h2>
<p class="First">Serum phosphate levels have been noted to decrease after administration of pamidronate disodium, presumably because of decreased release of phosphate from bone and increased renal excretion as parathyroid hormone levels, which are usually suppressed in <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> associated with malignancy, return toward normal.  Phosphate therapy was administered in 30% of the patients in response to a decrease in serum phosphate levels.  Phosphate levels usually returned toward normal within 7 to 10 days.</p>
<p>Urinary calcium/creatinine and urinary hydroxyproline/creatinine ratios decrease and usually return to within or below normal after treatment with pamidronate disodium.  These changes occur within the first week after treatment, as do decreases in serum calcium levels, and are consistent with an antiresorptive pharmacologic action.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ba76ba00-0584-4d63-8246-5c5fa32e873d"></a><a name="section-2.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">Hypercalcemia of Malignancy</span><br>
</h2>
<p class="First">Osteoclastic <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> resulting in excessive bone resorption is the underlying pathophysiologic derangement in metastatic bone disease and <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span>.  Excessive release of calcium into the blood as bone is resorbed results in <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>, with progressive <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and decreasing glomerular filtration rate.  This, in turn, results in increased renal resorption of calcium, setting up a cycle of worsening systemic <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.  Correction of excessive bone resorption and adequate fluid administration to correct volume deficits are therefore essential to the management of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.</p>
<p>Most cases of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> associated with malignancy occur in patients who have breast cancer; squamous-cell tumors of the lung or head and neck; renal-cell carcinoma; and certain hematologic malignancies, such as <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> and some types of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>.  A few less-common malignancies, including vasoactive intestinal-peptide-producing tumors and <span class="product-label-link" type="condition" conceptid="4321680" conceptname="Cholangiocarcinoma">cholangiocarcinoma</span>, have a high incidence of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> as a metabolic complication.  Patients who have <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> can generally be divided into two groups, according to the pathophysiologic mechanism involved.</p>
<p>In humoral <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, osteoclasts are activated and bone resorption is stimulated by factors such as parathyroid-hormone-related protein, which are elaborated by the tumor and circulate systemically.  Humoral <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> usually occurs in squamous-cell malignancies of the lung or head and neck or in genitourinary tumors such as renal-cell carcinoma or ovarian cancer.  Skeletal <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> may be absent or minimal in these patients.</p>
<p>Extensive invasion of bone by tumor cells can also result in <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> due to local tumor products that stimulate bone resorption by osteoclasts.  Tumors commonly associated with locally mediated <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> include breast cancer and <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>.</p>
<p>Total serum calcium levels in patients who have <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> may not reflect the severity of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, since concomitant <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span> is commonly present.  Ideally, <span class="product-label-link" type="condition" conceptid="4125860" conceptname="Calcium electrolyte">ionized calcium</span> levels should be used to diagnose and follow hypercalcemic conditions; however, these are not commonly or rapidly available in many clinical situations.  Therefore, adjustment of the total serum calcium value for differences in albumin levels is often used in place of measurement of <span class="product-label-link" type="condition" conceptid="4125860" conceptname="Calcium electrolyte">ionized calcium</span>; several nomograms are in use for this type of calculation (see <span class="Bold"><span class="Emphasis"><a href="#e8ebb69a-0c87-47a0-bfc1-10916be84600">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
<p><span class="Bold Italics"><span class="Emphasis">Clinical Trials</span></span></p>
<p>In one double-blind clinical trial, 52 patients who had <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> were enrolled to receive 30 mg, 60 mg, or 90 mg of pamidronate disodium as a single 24-hour intravenous infusion if their corrected serum calcium levels were ≥ 12 mg/dL after 48 hours of saline hydration.</p>
<p>The mean baseline-corrected serum calcium for the 30 mg, 60 mg, and 90 mg groups were 13.8 mg/dL, 13.8 mg/dL, and 13.3 mg/dL, respectively.</p>
<p>The majority of patients (64%) had decreases in albumin-corrected serum calcium levels by 24 hours after initiation of treatment.  Mean-corrected serum calcium levels at days 2 to 7 after initiation of treatment with pamidronate disodium were significantly reduced from baseline in all three dosage groups.  As a result, by 7 days after initiation of treatment with pamidronate disodium, 40%, 61%, and 100% of the patients receiving 30 mg, 60 mg, and 90 mg of pamidronate disodium, respectively, had normal-corrected serum calcium levels.  Many patients (33% to 53%) in the 60 mg and 90 mg dosage groups continued to have normal-corrected serum calcium levels, or a partial response (≥ 15% decrease of corrected serum calcium from baseline), at Day 14.</p>
<p>In a second double-blind, controlled clinical trial, 65 cancer patients who had corrected serum calcium levels of ≥ 12 mg/dL after at least 24 hours of saline hydration were randomized to receive either 60 mg of pamidronate disodium as a single 24-hour intravenous infusion or 7.5 mg/kg of etidronate disodium as a 2-hour intravenous infusion daily for 3 days.  Thirty patients were randomized to receive pamidronate disodium injection and 35 to receive etidronate disodium.</p>
<p>The mean baseline-corrected serum calcium for the pamidronate disodium injection 60 mg and etidronate disodium groups were 14.6 mg/dL and 13.8 mg/dL, respectively.</p>
<p>By Day 7, 70% of the patients in the pamidronate disodium group and 41% of the patients in the etidronate disodium group had normal-corrected serum calcium levels (P&lt;0.05).  When partial responders (≥ 15% decrease of serum calcium from baseline) were also included, the response rates were 97% for the pamidronate disodium group and 65% for the etidronate disodium group (P&lt;0.01).  Mean-corrected serum calcium for the pamidronate disodium and etidronate disodium groups decreased from baseline values to 10.4 and 11.2 mg/dL, respectively, on Day 7.  At Day 14, 43% of patients in the pamidronate disodium group and 18% of patients in the etidronate disodium group still had normal corrected serum calcium levels, or maintenance of a partial response.  For responders in the pamidronate disodium and etidronate disodium groups, the median duration of response was similar (7 and 5 days, respectively).  The time course of effect on corrected serum calcium is summarized in the following table.</p>
<p><span class="Bold"><span class="Emphasis">Table 2 </span></span></p>
<span class="Bold"><span class="Emphasis">Change in Corrected Serum Calcium by Time from Initiation of Treatment</span></span><table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">Time (hr)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom">
<p class="First">Mean Change from Baseline in Corrected </p>
<p> </p>
<p>Serum Calcium (mg/dL)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">Baseline</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">Pamidronate</p>
<p> </p>
<p> Disodium</p>
<p> </p>
<p> 14.6</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">Etidronate</p>
<p> </p>
<p> Disodium</p>
<p> </p>
<p> 13.8</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">P-Value<span class="Sup">1</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">24</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">-0.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">-0.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">48</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">-1.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">-1.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">72</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">-2.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">-2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">96</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">-3.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">-2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">&lt;0.01</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">168</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">-4.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">-2.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">&lt;0.0</p></td>
</tr>
</tbody></table>
<p><span class="Sup">1</span>Comparison between treatment groups</p>
<p>In a third multicenter, randomized, parallel double-blind trial, a group of 69 cancer patients with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> was enrolled to receive 60 mg of pamidronate disodium as a 4- or 24-hour infusion, which was compared to a saline treatment group.  Patients who had a corrected serum calcium level of ≥ 12 mg/dL after 24 hours of saline hydration were eligible for this trial.</p>
<p>The mean baseline-corrected serum calcium levels for pamidronate disodium 60 mg 4-hour infusion, pamidronate disodium 60 mg 24-hour infusion, and saline infusion were 14.2 mg/dL, 13.7 mg/dL, and 13.7 mg/dL, respectively.</p>
<p>By Day 7 after initiation of treatment, 78%, 61%, and 22% of the patients had normal-corrected serum calcium levels for the 60 mg 4-hour infusion, 60 mg 24-hour infusion, and saline infusion, respectively.  At Day 14, 39% of the patients in the pamidronate disodium 60 mg 4-hour infusion group and 26% of the patients in the pamidronate disodium 60 mg 24-hour infusion group had normal-corrected serum calcium levels or maintenance of a partial response.</p>
<p>For responders, the median duration of complete responses was 4 days and 6.5 days for pamidronate disodium 60 mg 4-hour infusion and pamidronate disodium 60 mg 24-hour infusion, respectively.</p>
<p>In all three trials, patients treated with pamidronate disodium had similar response rates in the presence or absence of bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>.  Concomitant administration of furosemide did not affect response rates.</p>
<p>Thirty-two patients who had recurrent or refractory <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> were given a second course of 60 mg of pamidronate disodium over a 4- or 24-hour period.  Of these, 41% showed a complete response and 16% showed a partial response to the retreatment, and these responders had about a 3 mg/dL <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in mean-corrected serum calcium levels 7 days after retreatment.</p>
<p>In a fourth multicenter, randomized, double-blind trial, 103 patients with cancer and <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> (corrected serum calcium ≥ 12 mg/dL) received 90 mg of pamidronate disodium as a 2-hour infusion.  The mean baseline corrected serum calcium was 14 mg/dL.  Patients were not required to receive IV hydration prior to drug administration, but all subjects did receive at least 500 mL of IV saline hydration concomitantly with the pamidronate infusion.  By Day 10 after drug infusion, 70% of patients had normal corrected serum calcium levels (&lt;10.8 mg/dL).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="aa96c1fc-017e-44af-8771-8f05b32773dc"></a><a name="section-2.5"></a><p></p>
<h2>Paget's Disease<br>
</h2>
<p class="First">Paget’s disease of bone (<span class="product-label-link" type="condition" conceptid="4196380" conceptname="Osteitis">osteitis</span> deformans) is an idiopathic disease characterized by chronic, focal areas of bone destruction complicated by concurrent excessive bone repair, affecting one or more bones.  These changes result in thickened but weakened bones that may <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> or bend under stress.  Signs and symptoms may be <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="4168498" conceptname="Deformity">deformity</span>, <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, neurological disorders resulting from cranial and spinal nerve entrapment and from spinal cord and brain stem compression, increased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> to the involved bone, increased serum alkaline phosphatase levels (reflecting increased bone formation) and/or urine hydroxyproline excretion (reflecting increased bone resorption).</p>
<p><span class="Bold Italics"><span class="Emphasis">Clinical Trials</span></span></p>
<p>In one double-blind clinical trial, 64 patients with moderate to severe Paget’s disease of bone were enrolled to receive 5 mg, 15 mg, or 30 mg of pamidronate disodium as a single 4-hour infusion on 3 consecutive days, for total doses of 15 mg, 45 mg, and 90 mg of pamidronate disodium.</p>
<p>The mean baseline serum alkaline phosphatase levels were 1,409 U/L, 983 U/L, and 1,085 U/L, and the mean baseline urine hydroxyproline/creatinine ratios were 0.25, 0.19, and 0.19 for the 15 mg, 45 mg, and 90 mg groups, respectively.</p>
<p>The effects of pamidronate disodium on serum alkaline phosphatase (SAP) and urine hydroxyproline/creatinine ratios (UOHP/C) are summarized in the following table:</p>
<p><span class="Bold"><span class="Emphasis">Table 3 </span></span></p>
<p><span class="Bold"><span class="Emphasis">Percent of Patients With Significant % Decreases in SAP and UOHP/C<br></span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">SAP </span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">UOHP/C </span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">% Decrease </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">15 mg </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">45 mg </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">90 mg </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">15 mg </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">45 mg </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">90 mg </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">≥ 50 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">26 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">33 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">60 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">15 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">47 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">72 </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">≥ 30 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">40 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">65 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">83 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">35 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">57 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">85 </p></td>
</tr>
</tbody></table>
<p>The median maximum percent decreases from baseline in serum alkaline phosphatase and urine hydroxyproline/creatinine ratios were 25%, 41%, and 57%, and 25%, 47%, and 61% for the 15 mg, 45 mg, and 90 mg groups, respectively.  The median time to response (≥ 50% decrease) for serum alkaline phosphatase was approximately 1 month for the 90 mg group, and the response duration ranged from 1 to 372 days.</p>
<p>No statistically significant differences between treatment groups, or statistically significant changes from baseline were observed for the <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> response, mobility, and global evaluation in the 45 mg and 90 mg groups.  Improvement in radiologic lesions occurred in some patients in the 90 mg group.</p>
<p>Twenty-five patients who had Paget’s disease were retreated with 90 mg of pamidronate disodium.  Of these, 44% had a ≥ 50% decrease in serum alkaline phosphatase from baseline after treatment, and 39% had a ≥ 50% decrease in urine hydroxyproline/creatinine ratio from baseline after treatment.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="e864bc3e-dfdc-4abd-8a7a-3c8c8ed10381"></a><a name="section-2.6"></a><p></p>
<h2>Osteolytic Bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">Metastases</span> of Breast Cancer and Osteolytic Lesions of <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span><br>
</h2>
<p class="First">Osteolytic bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> commonly occur in patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> or breast cancer.  These cancers demonstrate a phenomenon known as osteotropism, meaning they possess an extraordinary affinity for bone.  The distribution of osteolytic bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> in these cancers is predominantly in the axial skeleton, particularly the spine, pelvis, and ribs, rather than the appendicular skeleton, although lesions in the proximal femur and humerus are not uncommon.  This distribution is similar to the red bone marrow in which slow blood flow possibly assists attachment of metastatic cells.  The surface-to-volume ratio of trabecular bone is much higher than cortical bone, and therefore disease processes tend to occur more floridly in trabecular bone than at sites of cortical tissue.</p>
<p>These bone changes can result in patients having evidence of osteolytic skeletal destruction leading to severe <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> that requires either radiation therapy or narcotic analgesics (or both) for symptomatic relief.  These changes also cause pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of bone in both the axial and appendicular skeleton.  Axial skeletal <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the vertebral bodies may lead to <span class="product-label-link" type="condition" conceptid="4322945" conceptname="Spinal cord compression">spinal cord compression</span> or vertebral body collapse with significant neurologic complications.  Also, patients may experience episode(s) of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.</p>
<p><span class="Bold Italics"><span class="Emphasis">Clinical Trials</span></span></p>
<p>In a double-blind, randomized, placebo-controlled trial, 392 patients with advanced <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> were enrolled to receive pamidronate disodium or placebo in addition to their underlying antimyeloma therapy to determine the effect of pamidronate disodium on the occurrence of skeletal-related events (SREs).  SREs were defined as episodes of pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, radiation therapy to bone, surgery to bone, and <span class="product-label-link" type="condition" conceptid="4322945" conceptname="Spinal cord compression">spinal cord compression</span>.  Patients received either 90 mg of pamidronate disodium or placebo as a monthly 4-hour intravenous infusion for 9 months.  Of the 392 patients, 377 were evaluable for efficacy (196 pamidronate disodium, 181 placebo).  The proportion of patients developing any SRE was significantly smaller in the pamidronate disodium group (24% vs 41%, P&lt;0.001), and the mean skeletal morbidity rate (#SRE/year) was significantly smaller for pamidronate disodium patients than for placebo patients (mean: 1.1 vs 2.1, P&lt;.02).  The times to the first SRE occurrence, pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>, and radiation to bone were significantly longer in the pamidronate disodium group (P=.001, .006, and .046, respectively).  Moreover, fewer pamidronate disodium patients suffered any pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> (17% vs 30%, P=.004) or needed radiation to bone (14% vs 22%, P=.049).</p>
<p>In addition, decreases in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> scores from baseline occurred at the last measurement for those pamidronate disodium patients with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at baseline (P=.026) but not in the placebo group.  At the last measurement, a worsening from baseline was observed in the placebo group for the Spitzer quality of life variable (P&lt;.001) and ECOG performance status (P&lt;.011) while there was no significant deterioration from baseline in these parameters observed in pamidronate disodium-treated patients.*</p>
<p>After 21 months, the proportion of patients experiencing any skeletal event remained significantly smaller in the pamidronate disodium group than the placebo group (P=.015).  In addition, the mean skeletal morbidity rate (#SRE/year) was 1.3 vs 2.2 for pamidronate disodium patients vs placebo patients (P=.008), and time to first SRE was significantly longer in the pamidronate disodium group compared to placebo (P=.016).  Fewer pamidronate disodium patients suffered vertebral pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> (16% vs 27%, P=.005).  Survival of all patients was not different between treatment groups.</p>
<p>Two double-blind, randomized, placebo-controlled trials compared the safety and efficacy of 90 mg of pamidronate disodium infused over 2 hours every 3 to 4 weeks for 24 months to that of placebo in preventing SREs in breast cancer patients with osteolytic bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> who had one or more predominantly lytic <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> of at least 1 cm in diameter: one in patients being treated with antineoplastic chemotherapy and the second in patients being treated with hormonal antineoplastic therapy at trial entry. </p>
<p>382 patients receiving chemotherapy were randomized, 185 to pamidronate disodium and 197 to placebo.  372 patients receiving hormonal therapy were randomized, 182 to pamidronate disodium and 190 to placebo.  All but three patients were evaluable for efficacy.  Patients were followed for 24 months of therapy or until they went off study.  Median duration of follow-up was 13 months in patients receiving chemotherapy and 17 months in patients receiving hormone therapy.  Twenty-five percent of the patients in the chemotherapy study and 37% of the patients in the hormone therapy study received pamidronate disodium for 24 months.  The efficacy results are shown in Table 4 below:</p>
<p><span class="Bold"><span class="Emphasis">Table 4</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="3" valign="bottom"><p class="First">N </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="8" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Breast Cancer Patients Receiving Chemotherapy</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="8" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Breast Cancer Patients Receiving Hormonal Therapy</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">Any SRE</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">Radiation</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">Any SRE</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">Radiation</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">PD </p>
<p> </p>
<p>185</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First">P </p>
<p> </p>
<p>195</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">PD </p>
<p> </p>
<p>185</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First">P </p>
<p> </p>
<p>195</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">PD </p>
<p> </p>
<p>185</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">P </p>
<p> </p>
<p>195</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">PD </p>
<p> </p>
<p>182</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First">P </p>
<p> </p>
<p>189</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">PD </p>
<p> </p>
<p>182</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First">P </p>
<p> </p>
<p>189</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">PD </p>
<p> </p>
<p>182</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">P </p>
<p> </p>
<p>189</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Skeletal Morbidity Rate (#SRE/year) Mean </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">3.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">1.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">3.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">1.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">P-Value </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">&lt;.001</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">&lt;.001<span class="Sup">†</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">.018<span class="Sup">†</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">.021</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">.013<span class="Sup">†</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">.04<span class="Sup">†</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Proportion of patients having an SRE </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">46%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">65%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">28%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">45%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">36%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">49%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">55%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">63%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">31%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">40%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">45%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">55%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">P-Value </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">&lt;.001</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">&lt;.001<span class="Sup">†</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">.014<span class="Sup">†</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">.094</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">.058<span class="Sup">†</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">.054<span class="Sup">†</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Median Time to SRE (months) </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">13.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">NR**</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">14.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">25.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">13.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">10.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">7.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">NR**</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">23.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">20.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">12.8</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">P-Value </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">&lt;.001</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">&lt;.001<span class="Sup">†</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">.009†</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">.118</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">.016<span class="Sup">†</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">.113<span class="Sup">†</span></p></td>
</tr>
</tbody></table>
<p><span class="Sup">†</span><span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> and radiation to bone were two of several secondary endpoints.  The statistical significance of these analyses may be overestimated since numerous analyses were performed.</p>
<p>**NR = Not Reached.</p>
<p>Bone lesion response was radiographically assessed at baseline and at 3, 6, and 12 months.  The complete + partial response rate was 33% in pamidronate disodium patients and 18% in placebo patients treated with chemotherapy (P=.001).  No difference was seen between pamidronate disodium and placebo in hormonally-treated patients.  </p>
<p><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> and analgesic scores, ECOG performance status and Spitzer quality of life index were measured at baseline and periodically during the trials.  The changes from baseline to the last measurement carried forward are shown in Table 5 below:</p>
<p><span class="Bold"><span class="Emphasis">Table 5</span></span></p>
<p><span class="Bold"><span class="Emphasis">Mean Change (∆) from Baseline at Last Measurement</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="3" valign="top">
<p class="First"> </p>
<br><p> </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="5" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Breast Cancer Patients Receiving Chemotherapy</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="5" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Breast Cancer Patients Receiving Hormonal Therapy</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">Pamidronate Disodium</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">PD<span class="Sup">†</span> vs P‡</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">Pamidronate Disodium</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">PD<span class="Sup">† </span>vs P<span class="Sup">‡</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">N</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">Mean ∆</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">N</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">Mean ∆</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">P-Value*</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">N</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">Mean ∆</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">N</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">Mean ∆</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">P-Value*</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Score</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">175</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">+0.93</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">183</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">+1.69</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">.05</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">173</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">+0.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">179</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">+1.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">.007</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Analgesic Score</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">175</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">+0.74</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">183</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">+1.55</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">.009</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">173</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">+0.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">179</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">+2.28</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">&lt;.001</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">ECOG PS</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">178</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">+0.81</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">186</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">+1.19</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">.002</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">175</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">+0.95</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">182</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">+0.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">.773</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Spitzer QOL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">177</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">-1.76</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">185</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">-2.21</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">.103</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">173</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">-1.86</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">181</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">-2.05</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">.409</p></td>
</tr>
</tbody></table>
<p>Decreases in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, analgesic scores and ECOG PS, and increases in Spitzer QOL indicate an improvement from baseline.</p>
<p>*The statistical significance of analyses of these secondary endpoints of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, quality of life, and performance status in all three trials may be overestimated since numerous analyses were performed.</p>
<p><span class="Sup">†</span>Pamidronate Disodium</p>
<p>‡Placebo</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="c29396ab-1f95-4c9e-b5ee-e1e49a78d32c"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="34067-9">
<a name="b1231a12-f0bd-40ca-b183-dc2c4c458bbf"></a><a name="section-3.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">Hypercalcemia of Malignancy</span><br>
</h2>
<p class="First">Pamidronate Disodium Injection, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> associated with malignancy, with or without bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>.  Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium.  Vigorous saline hydration, an integral part of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment.  Mild or asymptomatic <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics).  Patients should be hydrated adequately throughout the treatment, but <span class="product-label-link" type="condition" conceptid="4266976" conceptname="Overhydration">overhydration</span>, especially in those patients who have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, must be avoided.  Diuretic therapy should not be employed prior to correction of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>.  The safety and efficacy of pamidronate disodium injection in the treatment of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> associated with <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> or with other non-tumor-related conditions has not been established.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="b718f1ed-0695-4283-bb39-e9520c51fe6d"></a><a name="section-3.2"></a><p></p>
<h2>Paget's Disease<br>
</h2>
<p class="First">Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone.  The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥ 3 times the upper limit of normal.  Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥ 50% in at least 50% of patients, and by ≥ 30% in at least 80% of patients.  Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="d6affa0c-21d0-4ea3-aafd-a86e4f90477e"></a><a name="section-3.3"></a><p></p>
<h2>Osteolytic Bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">Metastases</span> of Breast Cancer and Osteolytic Lesions of <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span><br>
</h2>
<p class="First">Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> of breast cancer and osteolytic lesions of <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>. The pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated (see <span class="Bold"><span class="Emphasis"><a href="#e864bc3e-dfdc-4abd-8a7a-3c8c8ed10381">CLINICAL PHARMACOLOGY, Osteolytic Bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">Metastases</span> of Breast Cancer and Osteolytic Lesions of <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span></a>, Clinical Trials</span></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="aa8430bb-a5ba-4752-a287-c5ead1d6d75b"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Pamidronate Disodium Injection is contraindicated in patients with clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to Pamidronate Disodium Injection or other bisphosphonates.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="e0c70d95-cb65-412d-a66b-2f3fcf30a9b7"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="34071-1">
<a name="fda29589-f96e-457d-bf9d-23e3206e7d7f"></a><a name="section-5.1"></a><p></p>
<h2>Deterioration in Renal Function<br>
</h2>
<p class="First">Bisphosphonates, including pamidronate disodium, have been associated with renal toxicity manifested as deterioration of renal function and potential <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. </p>
<p><span class="Bold"><span class="Emphasis">DUE TO THE RISK OF CLINICALLY SIGNIFICANT DETERIORATION IN RENAL FUNCTION, WHICH MAY PROGRESS TO <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">RENAL FAILURE</span>, SINGLE DOSES OF PAMIDRONATE DISODIUM SHOULD NOT EXCEED 90 MG (see <a href="#e8ebb69a-0c87-47a0-bfc1-10916be84600">DOSAGE AND ADMINISTRATION</a> for appropriate infusion durations).  Renal deterioration, progression to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and dialysis have been reported in patients after the initial or a single dose of pamidronate disodium.</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4030513" conceptname="Focal segmental glomerulosclerosis">Focal segmental glomerulosclerosis</span> (including the collapsing variant) with or without <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, which may lead to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, has been reported in pamidronate disodium-treated patients, particularly in the setting of <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> and breast cancer.  Some of these patients had gradual improvement in renal status after pamidronate disodium was discontinued.</p>
<p>Patients who receive pamidronate disodium should have serum creatinine assessed prior to each treatment.  Patients treated with pamidronate disodium for bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> should have the dose withheld if renal function has deteriorated (see <span class="Bold"><span class="Emphasis"><a href="#e8ebb69a-0c87-47a0-bfc1-10916be84600">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="c8534d04-a9cb-4943-b0a6-9cc197184574"></a><a name="section-5.2"></a><p></p>
<h2>PREGNANCY: PAMIDRONATE DISODIUM SHOULD NOT BE USED DURING PREGNANCY.<br>
</h2>
<p class="First">Pamidronate disodium may cause fetal harm when administered to a pregnant women (see <span class="Bold"><span class="Emphasis"><a href="#eac6664d-ce58-4f92-bbac-0939a9dc87cd">PRECAUTIONS, Pregnancy Category D</a></span></span>).</p>
<p>There are no studies in pregnant women using pamidronate disodium.  If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.  Women of childbearing potential should be advised to avoid becoming pregnant.</p>
<p>Studies conducted in young rats have reported the disruption of dental dentine formation following single- and multi-dose administration of bisphosphonates.  The clinical significance of these findings is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="b3101565-207d-473c-b26f-841aadb15ac7"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42232-9">
<a name="e7f2f0e4-65c2-452b-ac21-0eade877e142"></a><a name="section-6.1"></a><p></p>
<h2>General<br>
</h2>
<p class="First">Standard <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>-related metabolic parameters, such as serum levels of calcium, phosphate, magnesium, and potassium, should be carefully monitored following initiation of therapy with pamidronate disodium.  Cases of asymptomatic <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> (12%), <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (7%), <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> (11%), and <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> (5% to 12%), were reported in pamidronate disodium-treated patients.  Rare cases of symptomatic <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> (including <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span>) have been reported in association with pamidronate disodium therapy.  If <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> occurs, short-term calcium therapy may be necessary.  In Paget’s disease of bone, 17% of patients treated with 90 mg of pamidronate disodium showed serum calcium levels below 8 mg/dL.</p>
<p>Patients with a history of thyroid surgery may have relative <span class="product-label-link" type="condition" conceptid="140362" conceptname="Hypoparathyroidism">hypoparathyroidism</span> that may predispose to <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> with pamidronate disodium.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="cfb4361f-aab0-4257-a8b2-fe2c1778f146"></a><a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span><br>
</h2>
<p class="First">Pamidronate disodium is excreted intact primarily via the kidney, and the risk of renal adverse reactions may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Patients who receive pamidronate disodium should have serum creatinine assessed prior to each treatment.  In patients receiving pamidronate disodium for bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>, who show evidence of deterioration in renal function, pamidronate disodium treatment should be withheld until renal function returns to baseline (see <span class="Bold"><span class="Emphasis"><a href="#e0c70d95-cb65-412d-a66b-2f3fcf30a9b7">WARNINGS</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#e8ebb69a-0c87-47a0-bfc1-10916be84600">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
<p><span class="Bold"><span class="Emphasis">In clinical trials, patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (serum creatinine &gt; 3 mg/dL) have not been studied.  Limited pharmacokinetic data exist in patients with creatinine clearance &lt; 30 mL/min (see <a href="#c358522b-c3d4-4bf3-83b8-60b2b3910ebf">CLINICAL PHARMACOLOGY, Pharmacokinetics</a>). </span></span> For the treatment of bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>, the use of pamidronate disodium in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not recommended.  In other indications, clinical judgment should determine whether the potential benefit outweighs the potential risk in such patients.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="f88c32f3-c985-47ec-b47a-91df0a8abecc"></a><a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span> of the Jaw<br>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span> of the jaw (ONJ) has been reported predominantly in cancer patients treated with intravenous bisphosphonates, including pamidronate disodium.  Many of these patients were also receiving chemotherapy and corticosteroids which may be risk factors for ONJ.  Postmarketing experience and the literature suggest a greater frequency of reports of ONJ based on tumor type (advanced breast cancer, <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>), and dental status (dental extraction, <span class="product-label-link" type="condition" conceptid="134398" conceptname="Periodontal disease">periodontal disease</span>, local <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> including poorly fitting dentures).  Many reports of ONJ involved patients with signs of local <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> including <span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">osteomyelitis</span>.</p>
<p>Cancer patients should maintain good oral hygiene and should have a dental examination with preventive dentistry prior to treatment with bisphosphonates.</p>
<p>While on treatment, these patients should avoid invasive dental procedures if possible.  For patients who develop ONJ while on bisphosphonate therapy, dental surgery may exacerbate the condition.  For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of ONJ.  Clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment (see <span class="Bold"><span class="Emphasis"><a href="#d8613a51-2474-469a-bfcc-853d133817bc">ADVERSE REACTIONS</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ddd75be0-e636-4ca0-b207-53d41e26d5ed"></a><a name="section-6.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal Pain</span><br>
</h2>
<p class="First">In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> has been reported in patients taking bisphosphonates.  However, such reports have been infrequent.  This category of drugs includes pamidronate disodium for injection.  The time to onset of symptoms varied from one day to several months after starting the drug.  Most patients had relief of symptoms after stopping.  A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="b9bb4261-0615-4f53-8ea5-7c8a3646b379"></a><a name="section-6.5"></a><p></p>
<h2>Laboratory Tests<br>
</h2>
<p class="First">Patients who receive pamidronate disodium should have serum creatinine assessed prior to each treatment.  Serum calcium, electrolytes, phosphate, magnesium, and CBC, differential, and hematocrit/hemoglobin must be closely monitored in patients treated with pamidronate disodium. Patients who have preexisting <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> should be monitored carefully in the first 2 weeks following treatment.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="a1dabc45-f61f-4aad-8763-6bec8edc0cac"></a><a name="section-6.6"></a><p></p>
<h2>Drug Interactions<br>
</h2>
<p class="First">Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium.</p>
<p>Caution is indicated when pamidronate disodium is used with other potentially nephrotoxic drugs.</p>
<p>In <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> patients, the risk of renal dysfunction may be increased when pamidronate disodium is used in combination with thalidomide.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d41c6a8e-70c8-4101-9782-c176ebeff5d5"></a><a name="section-6.7"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility<br>
</h2>
<p class="First">In a 104-week carcinogenicity study (daily oral administration) in rats, there was a positive dose response relationship for benign adrenal <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> in males (P&lt;0.00001).  Although this condition was also observed in females, the incidence was not statistically significant.  When the dose calculations were adjusted to account for the limited oral bioavailability of pamidronate disodium in rats, the lowest daily dose associated with adrenal <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> was similar to the intended clinical dose. Adrenal <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> was also observed in low numbers in the control animals and is considered a relatively common spontaneous neoplasm in the rat.  Pamidronate disodium (daily oral administration) was not carcinogenic in an 80-week study in mice.</p>
<p>Pamidronate disodium was nonmutagenic in six mutagenicity assays: Ames test, <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> </span></span>and <span class="Italics"><span class="Emphasis">Escherichia</span></span>/liver-microsome test, nucleus-anomaly test, sister-chromatid-exchange study, point-mutation test, and micronucleus test in the rat.</p>
<p>In rats, decreased fertility occurred in first-generation offspring of parents who had received 150 mg/kg of pamidronate disodium orally; however, this occurred only when animals were mated with members of the same dose group.  Pamidronate disodium has not been administered intravenously in such a study.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="dcaa0de0-3f2c-4e1b-a7da-c8a7233df7e3"></a><a name="section-6.8"></a><p></p>
<h2>Animal Toxicology<br>
</h2>
<p class="First">In both rats and dogs, <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> has been associated with intravenous (bolus and infusion) administration of pamidronate disodium. </p>
<p>Two 7-day intravenous infusion studies were conducted in the dog wherein pamidronate disodium was given for 1, 4, or 24 hours at doses of 1 to 20 mg/kg for up to 7 days.  In the first study, the compound was well tolerated at 3 mg/kg (1.7 x highest recommended human dose [HRHD] for a single intravenous infusion) when administered for 4 or 24 hours, but renal findings such as elevated BUN and creatinine levels and <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">renal tubular necrosis</span> occurred when 3 mg/kg was infused for 1 hour and at doses of ≥ 10 mg/kg.  In the second study, slight <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">renal tubular necrosis</span> was observed in one male at 1 mg/kg when infused for 4 hours.  Additional findings included elevated BUN levels in several treated animals and renal tubular dilation and/or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> at ≥ 1 mg/kg after each infusion time.  </p>
<p>Pamidronate disodium was given to rats at doses of 2, 6, and 20 mg/kg and to dogs at doses of 2, 4, 6, and 20 mg/kg as a 1-hour infusion, once a week, for 3 months followed by a 1-month recovery period.  In rats, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> was observed at ≥ 6 mg/kg and included increased BUN and creatinine levels and tubular degeneration and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>.  These findings were still present at 20 mg/kg at the end of the recovery period.  In dogs, moribundity/<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and renal toxicity occurred at 20 mg/kg as did kidney findings of elevated BUN and creatinine levels at ≥ 6 mg/kg and renal tubular degeneration at ≥ 4 mg/kg.  The kidney changes were partially reversible at 6 mg/kg.  In both studies, the dose level that produced no adverse renal effects was considered to be 2 mg/kg (1.1 x HRHD for a single intravenous infusion).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="eac6664d-ce58-4f92-bbac-0939a9dc87cd"></a><a name="section-6.9"></a><p></p>
<h2>Pregnancy Category D<br>
</h2>
<p class="First"><span class="Bold"><span class="Emphasis">(see </span></span><span class="Bold"><span class="Emphasis"><a href="#e0c70d95-cb65-412d-a66b-2f3fcf30a9b7">WARNINGS</a>) </span></span></p>
<p>There are no adequate and well-controlled studies in pregnant women.</p>
<p>Bolus intravenous studies conducted in rats and rabbits determined that pamidronate disodium produces maternal toxicity and embryo/fetal effects when given during organogenesis at doses of 0.6 to 8.3 times the highest recommended human dose for a single intravenous infusion.  As it has been shown that pamidronate disodium can cross the placenta in rats and has produced marked maternal and nonteratogenic embryo/fetal effects in rats and rabbits, it should not be given to women during pregnancy.</p>
<p>Bisphosphonates are incorporated into the bone matrix, from where they are gradually released over periods of weeks to years.  The extent of bisphosphonate incorporation into adult bone, and hence, the amount available for release back into the systemic circulation, is directly related to the total dose and duration of bisphosphonate use.  Although there are no data on fetal risk in humans, bisphosphonates do cause fetal harm in animals, and animal data suggest that uptake of bisphosphonates into fetal bone is greater than into maternal bone.  Therefore, there is a theoretical risk of fetal harm (e.g., skeletal and other abnormalities) if a woman becomes pregnant after completing a course of bisphosphonate therapy.  The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration (intravenous vs oral) on this risk has not been established.</p>
<br>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="e0ea2af6-4131-4a58-9308-980b3d6147d9"></a><a name="section-6.10"></a><p></p>
<h2>Nursing Mothers<br>
</h2>
<p class="First">It is not known whether pamidronate disodium is excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when pamidronate disodium is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="fb18f155-ec98-430b-ad4b-8a0122564335"></a><a name="section-6.11"></a><p></p>
<h2>Pediatric Use<br>
</h2>
<p class="First">Safety and effectiveness of pamidronate disodium in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="a917057a-7a5e-4e45-9d0a-6b63477f1d86"></a><a name="section-6.12"></a><p></p>
<h2>Geriatric Use<br>
</h2>
<p class="First">Of the total number of subjects in clinical studies of pamidronate disodium for injection, approximately 20% were 65 and over, while approximately 15% were 75 and over.  No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.  In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="d8613a51-2474-469a-bfcc-853d133817bc"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34084-4">
<a name="a5ca8b42-1a41-4b07-9cbd-ecfdadab3816"></a><a name="section-7.1"></a><p></p>
<h2>Clinical Studies<br>
</h2>
<p class="First"><span class="Bold Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></span></span><span class="Bold Italics"><span class="Emphasis"> of Malignancy</span></span></p>
<p>Transient mild elevation of temperature by at least 1°C was noted 24 to 48 hours after administration of pamidronate disodium in 34% of patients in clinical trials.  In the saline trial, 18% of patients had a temperature elevation of at least 1°C 24 to 48 hours after treatment.</p>
<p>Drug-related local soft-tissue symptoms (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on palpation) at the site of catheter insertion were most common in patients treated with 90 mg of pamidronate disodium.  Symptomatic treatment resulted in rapid resolution in all patients.</p>
<p>Rare cases of <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, <span class="product-label-link" type="condition" conceptid="434944" conceptname="Scleritis">scleritis</span>, and <span class="product-label-link" type="condition" conceptid="4218083" conceptname="Episcleritis">episcleritis</span> have been reported, including one case of <span class="product-label-link" type="condition" conceptid="434944" conceptname="Scleritis">scleritis</span>, and one case of <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> upon separate rechallenges.</p>
<p>Five of 231 patients (2%) who received pamidronate disodium during the four U.S. controlled <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> clinical studies were reported to have had <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, two of whom had preexisting <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders.  None of the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> were considered to be drug-related by the investigators.  However, a possible relationship between the drug and the occurrence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> cannot be ruled out.  It should be noted that in the saline arm one patient (4%) had a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>.</p>
<p>There are no controlled clinical trials comparing the efficacy and safety of 90 mg pamidronate disodium over 24 hours to 2 hours in patients with <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span>.  However, a comparison of data from separate clinical trials suggests that the overall safety profile in patients who received 90 mg pamidronate disodium over 24 hours is similar to those who received 90 mg pamidronate disodium over 2 hours.  The only notable differences observed were an increase in the proportion of patients in the pamidronate disodium 24 hours group who experienced <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">fluid overload</span> and electrolyte/mineral abnormalities.</p>
<p>At least 15% of patients treated with pamidronate disodium for <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> also experienced the following adverse events during a clinical trial:</p>
<p><span class="Bold Italics"><span class="Emphasis">   General</span></span><span class="Italics"><span class="Emphasis">: </span></span><span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Fluid overload</span>, generalized <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
<p><span class="Bold Italics"><span class="Emphasis">   Cardiovascular</span></span><span class="Italics"><span class="Emphasis">: </span></span><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p>
<p><span class="Bold Italics"><span class="Emphasis">   Gastrointestinal</span></span><span class="Italics"><span class="Emphasis">: </span></span><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Bold Italics"><span class="Emphasis">   Genitourinary</span></span><span class="Italics"><span class="Emphasis">: </span></span><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></p>
<p><span class="Bold Italics"><span class="Emphasis">   Musculoskeletal</span></span><span class="Italics"><span class="Emphasis">: </span></span><span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone pain</span></p>
<p><span class="Bold Italics"><span class="Emphasis">   Laboratory Abnormality</span></span><span class="Italics"><span class="Emphasis">: </span></span><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span></p>
<p>Many of these adverse experiences may have been related to the underlying disease state.</p>
<p>Table 6 lists the adverse experiences considered to be treatment-related during comparative, controlled U.S. trials.</p>
<p><span class="Bold"><span class="Emphasis">Table 6</span></span></p>
<p><span class="Bold"><span class="Emphasis">Treatment-Related Adverse Experiences Reported in Three U.S. Controlled Clinical Trials</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="1" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="5" valign="bottom"><p class="First">Percent of Patients</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">Pamidronate Disodium</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">Etidronate</p>
<p>Disodium</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">Saline</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">60 mg </p>
<p><span class="Underline"><span class="Emphasis">over</span></span><span class="Underline"><span class="Emphasis"> 4 hr</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">60 mg </p>
<p><span class="Underline"><span class="Emphasis">over</span></span><span class="Underline"><span class="Emphasis"> 24 hr</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">90 mg </p>
<p><span class="Underline"><span class="Emphasis">over</span></span><span class="Underline"><span class="Emphasis"> 24 hr</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">7.5 mg/kg </p>
<p><span class="Underline"><span class="Emphasis">x</span></span><span class="Underline"><span class="Emphasis"> 3 days</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">n=23</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">n=73</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">n=17</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">n=35</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">n=23</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="6" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">General </span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">26</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">Fluid overload</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Infusion-site reaction </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Moniliasis</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="6"><p class="First"><span class="Bold"><span class="Emphasis">Gastrointestinal </span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal hemorrhage</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="6"><p class="First"><span class="Bold"><span class="Emphasis">Respiratory </span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">Rales</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory infection</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="6"><p class="First"><span class="Bold"><span class="Emphasis">CNS </span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="6"><p class="First"><span class="Bold"><span class="Emphasis">Cardiovascular </span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">Atrial flutter</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac failure</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="6">
<span class="Bold"><span class="Emphasis">Endocrine
            </span></span><br>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="6"><p class="First"><span class="Bold"><span class="Emphasis">Hemic and Lymphatic </span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="6">
<span class="Bold"><span class="Emphasis">Musculoskeletal</span></span><br>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="6"><p class="First"><span class="Bold"><span class="Emphasis">Urogenital</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">Uremia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="6" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Laboratory Abnormalities </span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" rowspan="1" valign="top"><p class="First">Abnormal liver function</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="1" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="1" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="1" valign="bottom"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="1" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="1" valign="bottom"><p class="First">0</p></td>
</tr>
</tbody></table>
<span class="Bold Italics"><span class="Emphasis">Paget’s Disease</span></span><p>Transient mild elevation of temperature &gt;1°C above pretreatment baseline was noted within 48 hours after completion of treatment in 21% of the patients treated with 90 mg of pamidronate disodium in clinical trials.</p>
<p>Drug-related <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span> and nervous system symptoms (<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>) were more common in patients with Paget’s disease treated with 90 mg of pamidronate disodium than in patients with <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> treated with the same dose. </p>
<p>Adverse experiences considered to be related to trial drug, which occurred in at least 5% of patients with Paget’s disease treated with 90 mg of pamidronate disodium in two U.S. clinical trials, were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, and <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>.</p>
<p>At least 10% of all pamidronate disodium-treated patients with Paget’s disease also experienced the following adverse experiences during clinical trials:</p>
<p><span class="Bold Italics"><span class="Emphasis">   Cardiovascular</span></span><span class="Italics"><span class="Emphasis">: </span></span><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p>
<p><span class="Bold Italics"><span class="Emphasis">   Musculoskeletal</span></span><span class="Italics"><span class="Emphasis">: </span></span><span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">Arthrosis</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span></p>
<p><span class="Bold Italics"><span class="Emphasis">   Nervous system</span></span><span class="Italics"><span class="Emphasis">: </span></span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p>
<p>Most of these adverse experiences may have been related to the underlying disease state.</p>
<p><span class="Bold Italics"><span class="Emphasis">Osteolytic Bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">Metastases</span> of Breast Cancer and Osteolytic Lesions of <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span></span></span></p>
<p>The most commonly reported (&gt;15%) adverse experiences occurred with similar frequencies in the pamidronate disodium- and placebo-treatment groups, and most of these adverse experiences may have been related to the underlying disease state or cancer therapy (see Table 7 below).</p>
<p><span class="Bold"><span class="Emphasis">Table 7</span></span></p>
<p><span class="Bold"><span class="Emphasis">Commonly Reported Adverse Experiences in Three U.S. Controlled Clinical Trials   </span></span></p>
<table width="474.85pt"><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">Pamidronate</p>
<p>Disodium</p>
<p>90 mg</p>
<p><span class="Underline"><span class="Emphasis">over 4 hours</span></span></p>
<p>N=205</p>
<p>%</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Underline"><span class="Emphasis">Placebo</span></span></p>
<p>N=187</p>
<p>%</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">Pamidronate</p>
<p>Disodium</p>
<p>90 mg</p>
<p><span class="Underline"><span class="Emphasis">over 2 hours</span></span></p>
<p>N=367</p>
<p>%</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Underline"><span class="Emphasis">Placebo</span></span></p>
<p>N=386</p>
<p>%</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">All</p>
<p>Pamidronate</p>
<p>Disodium</p>
<p><span class="Underline"><span class="Emphasis">90 mg</span></span></p>
<p>N=572</p>
<p>%</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Underline"><span class="Emphasis">Placebo</span></span></p>
<p>N=573</p>
<p>%</p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="7"><p class="First"><span class="Bold"><span class="Emphasis">General </span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">16.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">17.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">25.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">19.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">22.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">18.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">31.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">28.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">40.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">28.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">37.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">29</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">38.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">38</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">38.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">32.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">38.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">34</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">Metastases</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">31.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">24.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">20.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">17.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">13.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">11.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">18.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">14.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">16.1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="7"><p class="First"><span class="Bold"><span class="Emphasis">Digestive System </span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">17.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">17.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">31.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">24.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">26</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">22.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">28.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">31.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">36</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">38.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">33.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">35.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">26.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">26.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">29.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">30.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">28.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">29.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">17.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">13.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">18.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">22.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">17.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">35.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">37.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">63.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">59.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">53.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">51.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Pain Abdominal</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">19.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">24.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">18.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">22.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">17.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">16.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">19.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">46.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">39.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">35.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">32.8</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="7"><p class="First"><span class="Bold"><span class="Emphasis">Hemic and Lymphatic</span></span> </p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">47.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">41.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">39.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">36.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">42.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">38.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">Granulocytopenia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">20.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">15.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">19.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">20.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">19.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">18.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">16.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">17.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">12.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">14.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">15</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="7" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Musculoskeletal System</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgias</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">10.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">15.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">12.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">13.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">10.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">25.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">26.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">22.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">26</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">20.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Skeletal pain</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">61</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">71.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">70</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">75.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">66.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">74</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="7"><p class="First"><span class="Bold"><span class="Emphasis">CNS </span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">7.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">9.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">16.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">14.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">14.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">24.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">19.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">27.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">23.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">26.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">22.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">17.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">17.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">25.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">19.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">22.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">19.1</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="7"><p class="First"><span class="Bold"><span class="Emphasis">Respiratory System </span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">26.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">22.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">25.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">19.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">25.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">20.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">21.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">35.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">24.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">30.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">23.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural Effusion</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">9.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">10.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">7.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">14.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">16.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">16.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">10.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">15.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">12</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">32.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">28.3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">19.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">20.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">24.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">22.9</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="7" valign="top">
<span class="Bold"><span class="Emphasis">Urogenital System </span></span><br>
</td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">15.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">9.1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">20.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> 17.6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">18.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> 15.6</p></td>
</tr>
</tbody></table>
<p>Of the toxicities commonly associated with chemotherapy, the frequency of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> were slightly more common in the pamidronate disodium patients whereas <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> occurred at a frequency similar to that in placebo patients.  In the breast cancer trials, mild elevations of serum creatinine occurred in 18.5% of pamidronate disodium patients and 12.3% of placebo patients.  Mineral and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span>, including <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, were reported rarely and in similar percentages of pamidronate disodium-treated patients compared with those in the placebo group.  The reported frequencies of <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, and <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> for pamidronate disodium-treated patients were 3.3%, 10.5%, 1.7%, and 4.4%, respectively, and for placebo-treated patients were 1.2%, 12%, 1.7%, and 4.5%, respectively.  In previous <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> trials, patients treated with pamidronate disodium (60 or 90 mg over 24 hours) developed electrolyte abnormalities more frequently (see <span class="Bold"><span class="Emphasis"><a href="#d8613a51-2474-469a-bfcc-853d133817bc">ADVERSE REACTIONS</a><a href="#d8613a51-2474-469a-bfcc-853d133817bc">, <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">Hypercalcemia of Malignancy</span></a></span></span>).</p>
<p><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgias</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span> were reported slightly more frequently in the pamidronate disodium group than in the placebo group (13.6% and 26% vs 10.8% and 20.1%, respectively).</p>
<p>In <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> patients, there were five pamidronate disodium-related serious and unexpected adverse experiences.  Four of these were reported during the 12-month extension of the <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> trial.  Three of the reports were of worsening renal function developing in patients with progressive <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> or <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>-associated <span class="product-label-link" type="condition" conceptid="432595" conceptname="Amyloidosis">amyloidosis</span>.  The fourth report was the <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">adult respiratory distress syndrome</span> developing in a patient recovering from <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> and acute <span class="product-label-link" type="condition" conceptid="4009168" conceptname="Gangrene of gallbladder">gangrenous cholecystitis</span>.  One pamidronate disodium-treated patient experienced an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> characterized by swollen and <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">itchy eyes</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span>, and scratchy throat within 24 hours after the sixth infusion.</p>
<p>In the breast cancer trials, there were four pamidronate disodium-related adverse experiences, all moderate in severity, that caused a patient to discontinue participation in the trial.  One was due to <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>, another to <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>.  One pamidronate disodium patient discontinued the trial due to a symptomatic <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>.  Another pamidronate disodium patient discontinued therapy due to severe <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> after each infusion, which the investigator felt was trial-drug-related.</p>
<p><span class="Bold Italics"><span class="Emphasis">Renal Toxicity</span></span></p>
<p>In a study of the safety and efficacy of pamidronate disodium injection 90 mg (2 hour infusion) versus zoledronic acid injection 4 mg (15 minute infusion) in bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> or breast cancer, renal deterioration was defined as an increase in serum creatinine of 0.5 mg/dL for patients with normal baseline creatinine (&lt;1.4 mg/dL) or an increase of 1 mg/dL for patients with an abnormal baseline creatinine (≥ 1.4 mg/dL).  The following are data on the incidence of renal deterioration in patients in this trial.  See Table 8 below.</p>
<p><span class="Bold"><span class="Emphasis"><span class="Bold"><span class="Emphasis">Table 8</span></span><br><span class="Bold"><span class="Emphasis">Incidence of Renal Function Deterioration in</span></span> <span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span> and Breast Cancer Patients with Normal and</span></span> <span class="Bold"><span class="Emphasis">Abnormal Serum Creatinine at Baseline*</span></span> </span></span> </p>
<table width="295.65pt"><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">Patient</p>
<p>Population/</p>
<p>Baseline</p>
<p>Creatinine</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First">Pamidronate</p>
<p>Disodium</p>
<p>Injection</p>
<p>90 mg/2 hours</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="bottom">
<p class="First">Zoledronic Acid</p>
<p>Injection</p>
<p>4 mg/15 minutes</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">n/N</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">n/N</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">Normal</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">20/246</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(8.1%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">23/246</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(9.3%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">Abnormal</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2/22</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(9.1%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1/26</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(3.8%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">Total</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">22/268</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(8.2%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">24/272</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">(8.8%)</p></td>
</tr>
</tbody></table>
<p>*<span class="Italics"><span class="Emphasis">Patients were randomized following the 15 minute infusion amendment for the zoledronic acid injection arm.</span></span><span class="Bold"><span class="Emphasis"><br></span></span></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="c185bb78-8c9f-460e-b1d0-2fe69b68ddac"></a><a name="section-7.2"></a><p></p>
<h2>Post-Marketing Experience<br>
</h2>
<p class="First">The following adverse reactions have been reported in post-marketing use: <span class="Bold Italics"><span class="Emphasis">General</span></span>: reactivation of Herpes simplex and <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms; <span class="Bold Italics"><span class="Emphasis">CNS</span></span>: <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="4275889" conceptname="Visual hallucinations">visual hallucinations</span>, sometimes in the presence of <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>; <span class="Bold Italics"><span class="Emphasis">Skin</span></span>: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; <span class="Bold Italics"><span class="Emphasis">Special senses</span></span>: <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, orbital <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>; <span class="Bold Italics"><span class="Emphasis">Renal</span></span>: <span class="product-label-link" type="condition" conceptid="4030513" conceptname="Focal segmental glomerulosclerosis">focal segmental glomerulosclerosis</span> including the collapsing variant, <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>; <span class="Bold Italics"><span class="Emphasis">Laboratory abnormalities</span></span>: <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">hypernatremia</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>.  Rare instances of allergic manifestations have been reported, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and, very rarely, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>. Pamidronate disodium is contraindicated in patients with clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to pamidronate disodium or other bisphosphonates (see <span class="Bold"><span class="Emphasis"><a href="#aa8430bb-a5ba-4752-a287-c5ead1d6d75b">CONTRAINDICATIONS</a></span></span>).</p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">osteonecrosis</span> (primarily involving the jaw) have been reported predominantly in cancer patients treated with intravenous bisphosphonates, including pamidronate disodium.  Many of these patients were also receiving chemotherapy and corticosteroids which may be risk factors for ONJ.  Data suggest a greater frequency of reports of ONJ in certain cancers, such as advanced breast cancer and <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>.  The majority of the reported cases are in cancer patients following invasive dental procedures, such as tooth extraction.  It is therefore prudent to avoid invasive dental procedures as recovery may be prolonged (see <span class="Bold"><span class="Emphasis"><a href="#b3101565-207d-473c-b26f-841aadb15ac7">PRECAUTIONS</a></span></span>).</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="e3565271-f02f-46c8-99e1-d90f0810a7b3"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There have been several cases of drug maladministration of intravenous pamidronate disodium in <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> patients with total doses of 225 mg to 300 mg given over 2 1/2 to 4 days.  All of these patients survived, but they experienced <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> that required intravenous and/or oral administration of calcium.  <span class="Bold"><span class="Emphasis">Single doses of pamidronate disodium should not exceed 90 mg and the duration of the intravenous infusion should be no less than 2 hours (see </span></span><span class="Bold"><span class="Emphasis"><a href="#e0c70d95-cb65-412d-a66b-2f3fcf30a9b7">WARNINGS</a>).</span></span></p>
<p>In addition, one obese woman (95 kg) who was treated with 285 mg of pamidronate disodium/day for 3 days experienced high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (39.5°C), <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (from 170/90 mmHg to 90/60 mmHg), and transient <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, noted about 6 hours after the first infusion.  The <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> were rapidly corrected with steroids.</p>
<p>If overdosage occurs, symptomatic <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> could also result; such patients should be treated with short-term intravenous calcium.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="e8ebb69a-0c87-47a0-bfc1-10916be84600"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="34068-7">
<a name="b0746228-36f2-496c-9390-c971a2daeda1"></a><a name="section-9.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">Hypercalcemia of Malignancy</span><br>
</h2>
<p class="First">Consideration should be given to the severity of as well as the symptoms of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.  Vigorous saline hydration alone may be sufficient for treating mild, asymptomatic <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.  <span class="product-label-link" type="condition" conceptid="4266976" conceptname="Overhydration">Overhydration</span> should be avoided in patients who have potential for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>.  In <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> associated with hematologic malignancies, the use of glucocorticoid therapy may be helpful.</p>
<p><span class="Bold Italics"><span class="Emphasis">Moderate <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></span></span></p>
<p><span class="Bold"><span class="Emphasis">The recommended dose of pamidronate disodium in moderate <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> (corrected serum calcium* of approximately 12 to 13.5 mg/dL) is 60 to 90 </span></span><span class="Bold"><span class="Emphasis">mg given as a SINGLE-DOSE, intravenous infusion over 2 to 24 hours.  Longer infusions (i.e., &gt;2 hours) may reduce the risk for renal toxicity, particularly in patients with preexisting <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</span></span></p>
<p><span class="Bold Italics"><span class="Emphasis">Severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></span></span></p>
<p><span class="Bold"><span class="Emphasis">The recommended dose of pamidronate disodium in severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> (corrected serum calcium* &gt;13.5 mg/dL) is 90 mg given as a SINGLE-DOSE, intravenous infusion over 2 to 24 hours.  Longer infusions (i.e., &gt;2 hours) may reduce the risk for renal toxicity, particularly in patients with preexisting <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</span></span></p>
<p>_______________________</p>
<p>*Albumin-corrected serum calcium (CCa, mg/dL) = serum calcium, mg/dL + 0.8 (4-serum albumin, g/dL).</p>
<p><span class="Bold Italics"><span class="Emphasis">Retreatment</span></span></p>
<p>A limited number of patients have received more than one treatment with pamidronate disodium for <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>.  Retreatment with pamidronate disodium, in patients who show complete or partial response initially, may be carried out if serum calcium does not return to normal or remain normal after initial treatment.  <span class="Bold"><span class="Emphasis">It is recommended that a minimum of 7 days elapse before retreatment, to allow for full response to the initial dose</span></span>.  The dose and manner of retreatment is identical to that of the initial therapy.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="d4bd8fd4-5aa7-4c8d-afeb-7b28b674682f"></a><a name="section-9.2"></a><p></p>
<h2>Paget's Disease<br>
</h2>
<p class="First"><span class="Bold"><span class="Emphasis">The recommended dose of pamidronate disodium in patients with moderate to severe Paget’s disease of bone is 30 mg daily, administered as a 4-hour infusion on 3 consecutive days for a total dose of 90 mg.</span></span></p>
<p><span class="Bold Italics"><span class="Emphasis">Retreatment</span></span></p>
<p>A limited number of patients with Paget’s disease have received more than one treatment of pamidronate disodium in clinical trials.  When clinically indicated, patients should be retreated at the dose of initial therapy.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dd3a6e31-dc6e-4e92-8ef4-7277df50de01"></a><a name="section-9.3"></a><p></p>
<h2>Osteolytic Bone Lesions of <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span><br>
</h2>
<p class="First"><span class="Bold"><span class="Emphasis">The recommended dose of pamidronate disodium in patients with osteolytic bone lesions of <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> is 90 mg administered as a 4-hour infusion given on a monthly basis.</span></span></p>
<p>Patients with marked Bence-Jones <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> should receive adequate hydration prior to pamidronate disodium infusion.</p>
<p>Limited information is available on the use of pamidronate disodium in <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> patients with a serum creatinine ≥ 3 mg/dL.</p>
<p>Patients who receive pamidronate disodium should have serum creatinine assessed prior to each treatment.  Treatment should be withheld for renal deterioration. In a clinical study, renal deterioration was defined as follows:</p>
<p>   • For patients with normal baseline creatinine, increase of 0.5 mg/dL.</p>
<p>   • For patients with abnormal baseline creatinine, increase of 1 mg/dL.</p>
<p>In this clinical study, pamidronate disodium treatment was resumed only when the creatinine returned to within 10% of the baseline value.</p>
<p>The optimal duration of therapy is not yet known, however, in a study of patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">myeloma</span>, final analysis after 21 months demonstrated overall benefits (see <span class="Bold Italics"><span class="Emphasis">Clinical Trials</span></span>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="df72935b-61e6-405b-a18e-1bc444f138db"></a><a name="section-9.4"></a><p></p>
<h2>Osteolytic Bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">Metastases</span> of Breast Cancer<br>
</h2>
<p class="First"><span class="Bold"><span class="Emphasis">The recommended dose of pamidronate disodium in patients with osteolytic bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> is 90 mg administered over a 2-hour infusion given every 3 to 4 weeks.</span></span></p>
<p>Pamidronate disodium has been frequently used with doxorubicin, fluorouracil, cyclophosphamide, methotrexate, mitoxantrone, vinblastine, dexamethasone, prednisone, melphalan, vincristine, megesterol, and tamoxifen.  It has been given less frequently with etoposide, cisplatin, cytarabine, paclitaxel, and aminoglutethimide.</p>
<p>Patients who receive pamidronate disodium should have serum creatinine assessed prior to each treatment.  Treatment should be withheld for renal deterioration. In a clinical study, renal deterioration was defined as follows:</p>
<p>   • For patients with normal baseline creatinine, increase of 0.5 mg/dL.</p>
<p>   • For patients with abnormal baseline creatinine, increase of 1 mg/dL.</p>
<p>In this clinical study, pamidronate disodium treatment was resumed only when the creatinine returned to within 10% of the baseline value.</p>
<p>The optimal duration of therapy is not known, however, in two breast cancer studies, final analyses performed after 24 months of therapy demonstrated overall benefits (see <span class="Bold Italics"><span class="Emphasis">Clinical Trials</span></span>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="d0490a16-3cbd-4000-afac-8bd3f17349aa"></a><a name="section-9.5"></a><p></p>
<h2>Calcium and Vitamin D Supplementation<br>
</h2>
<p class="First">In the absence of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, patients with predominantly lytic bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> or <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>, who are at risk of calcium or <span class="product-label-link" type="condition" conceptid="436070" conceptname="Vitamin D deficiency">vitamin D deficiency</span>, and patients with Paget’s disease of the bone, should be given oral calcium and vitamin D supplementation in order to minimize the risk of <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="b2128c20-5464-486d-853d-046c2c08bd92"></a><a name="section-9.6"></a><p></p>
<h2>Preparation of Infusion<br>
</h2>
<p class="First"><span class="Bold Italics"><span class="Emphasis">Method of Administration</span></span></p>
<p><span class="Bold"><span class="Emphasis">DUE TO THE RISK OF CLINICALLY SIGNIFICANT DETERIORATION IN RENAL FUNCTION, WHICH MAY PROGRESS TO <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">RENAL FAILURE</span>, SINGLE DOSES OF PAMIDRONATE DISODIUM SHOULD NOT EXCEED 90 MG (see</span></span> <span class="Bold"><span class="Emphasis"><a href="#e0c70d95-cb65-412d-a66b-2f3fcf30a9b7">WARNINGS</a>).</span></span></p>
<p>There must be strict adherence to the intravenous administration recommendations for pamidronate disodium in order to decrease the risk of deterioration in renal function.</p>
<p><span class="Bold Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">Hypercalcemia of Malignancy</span></span></span></p>
<p>The daily dose must be administered as an intravenous infusion over at least 2 to 24 hours for the 60 mg dose and the 90 mg doses.  The recommended dose should be diluted in 1000 mL of sterile 0.45% or 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP.  This infusion solution is stable for up to 24 hours at room temperature.</p>
<p><span class="Bold Italics"><span class="Emphasis">Paget’s Disease</span></span></p>
<p>The recommended daily dose of 30 mg should be diluted in 500 mL of sterile 0.45% or 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP, and administered over a 4-hour period for 3 consecutive days.</p>
<p><span class="Bold Italics"><span class="Emphasis">Osteolytic Bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">Metastases</span> of Breast Cancer</span></span></p>
<p>The recommended dose of 90 mg should be diluted in 250 mL of sterile 0.45% or 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP, and administered over a 2-hour period every 3 to 4 weeks.</p>
<p><span class="Bold Italics"><span class="Emphasis">Osteolytic Bone Lesions of <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span></span></span></p>
<p>The recommended dose of 90 mg should be diluted in 500 mL of sterile 0.45% or 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP, and administered over a 4-hour period on a monthly basis.</p>
<p><span class="Bold"><span class="Emphasis">Pamidronate disodium must not be mixed with calcium-containing infusion solutions, such as Ringer’s solution, and should be given in a single intravenous solution and line separate from all other drugs.</span></span></p>
<span class="Bold"><span class="Emphasis">Note: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</span></span><br>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="a5ee1d17-fc7b-4cf1-bd68-3fe68c37e065"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">Product</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">730410</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-734-10</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Pamidronate Disodium Injection,</p>
<p>30 mg/10 mL (3 mg/mL),</p>
<p>in a 10 mL single dose vial,</p>
<p>packaged individually.</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">730510</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-735-10</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Pamidronate Disodium Injection,</p>
<p>90 mg/10 mL (9 mg/mL),</p>
<p>in a 10 mL single dose vial,</p>
<p>packaged individually.</p>
</td>
</tr>
</tbody></table>
<p class="First">Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</p>
<p>This container closure is not made with natural rubber latex.</p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="b88a891b-4561-4f5f-b0c2-a2a8ad2c8705"></a><a name="section-11"></a><p></p>
<h1></h1>
<div class="Figure"><img alt="APP Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad1b83f9-ddf7-44b7-9234-77d6872e4825&amp;name=pamidronate-disodium-injection-figure-3-add_band_logo.jpg"></div>
<p class="First">45860G</p>
<p>Revised: July 2011</p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="e97b04ae-9d34-45ac-b66e-18d88bf60f6f"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Pamidronate Disodium 30 mg/10 mL Single Dose Vial Label</span></span> </p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-734-10</p>
<p>730410</p>
<p><span class="Bold"><span class="Emphasis">PAMIDRONATE DISODIUM INJECTION</span></span></p>
<p><span class="Bold"><span class="Emphasis">30 mg/10 mL (3 mg/mL)</span></span></p>
<p>For Intravenous Infusion</p>
<p>Do not mix with calcium-containing infusion solutions.</p>
<p>Further Dilution Required.</p>
<p><span class="Bold"><span class="Emphasis">10 mL </span></span>Single Dose Vial</p>
<p>Rx only</p>
<p><img alt="30 mg/10 mL Pamidronate Disodium Vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad1b83f9-ddf7-44b7-9234-77d6872e4825&amp;name=pamidronate-disodium-injection-figure-4-730410vial.jpg"></p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Pamidronate Disodium 30 mg/10 mL Single Dose Vial Carton Panel</span></span> </p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-734-10</p>
<p>730410</p>
<p><span class="Bold"><span class="Emphasis">PAMIDRONATE DISODIUM INJECTION</span></span></p>
<p><span class="Bold"><span class="Emphasis">30 mg/10 mL (3 mg/mL)</span></span></p>
<p>For Intravenous Infusion</p>
<p>Do not mix with calcium-containing infusion solutions.</p>
<p>Further Dilution Required.</p>
<p><span class="Bold"><span class="Emphasis">10 mL </span></span>Single Dose Vial</p>
<p>Rx only</p>
<br><p><img alt="30 mg/10 mL Pamidronate Disodium Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad1b83f9-ddf7-44b7-9234-77d6872e4825&amp;name=pamidronate-disodium-injection-figure-5-730410carton.jpg"></p>
<p> 
</p>
<p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Pamidronate Disodium 90 mg/10 mL Single Dose Vial Label</span></span> </p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-735-10</p>
<p>730510</p>
<p><span class="Bold"><span class="Emphasis">PAMIDRONATE DISODIUM INJECTION</span></span></p>
<p><span class="Bold"><span class="Emphasis">90 mg/10 mL (9 mg/mL)</span></span></p>
<p>For Intravenous Infusion</p>
<p>Do not mix with calcium-containing infusion solutions.</p>
<p>Further Dilution Required.</p>
<p><span class="Bold"><span class="Emphasis">10 mL </span></span>Single Dose Vial</p>
<p>Rx only</p>
<p><img alt="90 mg/10 mL Pamidronate Disodium Vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad1b83f9-ddf7-44b7-9234-77d6872e4825&amp;name=pamidronate-disodium-injection-figure-6-730510vial.jpg"></p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Pamidronate Disodium 90 mg/10 mL Single Dose Vial Carton Panel</span></span> </p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-735-10</p>
<p>730510</p>
<p><span class="Bold"><span class="Emphasis">PAMIDRONATE DISODIUM INJECTION</span></span></p>
<p><span class="Bold"><span class="Emphasis">90 mg/10 mL (9 mg/mL)</span></span></p>
<p>For Intravenous Infusion</p>
<p>Do not mix with calcium-containing infusion solutions.</p>
<p>Further Dilution Required.</p>
<p><span class="Bold"><span class="Emphasis">10 mL </span></span>Single Dose Vial</p>
<p>Rx only</p>
<p> <img alt="90 mg/10 mL Pamidronate Disodium Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad1b83f9-ddf7-44b7-9234-77d6872e4825&amp;name=pamidronate-disodium-injection-figure-7-730510carton.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PAMIDRONATE DISODIUM 		
					</strong><br><span class="contentTableReg">pamidronate disodium injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-734</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PAMIDRONATE DISODIUM</strong> (PAMIDRONIC ACID) </td>
<td class="formItem">PAMIDRONATE DISODIUM</td>
<td class="formItem">3 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">47 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PHOSPHORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-734-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076207</td>
<td class="formItem">05/19/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PAMIDRONATE DISODIUM 		
					</strong><br><span class="contentTableReg">pamidronate disodium injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-735</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PAMIDRONATE DISODIUM</strong> (PAMIDRONIC ACID) </td>
<td class="formItem">PAMIDRONATE DISODIUM</td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">37.5 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PHOSPHORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-735-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076207</td>
<td class="formItem">05/19/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>APP Pharmaceuticals, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">APP Pharmaceuticals, LLC</td>
<td class="formItem"></td>
<td class="formItem">840771732</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>80ed4c20-1e43-4fe2-bfd9-64652ba75471</div>
<div>Set id: ad1b83f9-ddf7-44b7-9234-77d6872e4825</div>
<div>Version: 1</div>
<div>Effective Time: 20110808</div>
</div>
</div> <div class="DistributorName">APP Pharmaceuticals, LLC</div></p>
</body></html>
